Zanubrutinib + Sonrotoclax + Obinutuzumab for Chronic Lymphocytic Leukemia
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical research study is to learn if the combination of zanubrutinib, sonrotoclax, and obinutuzumab can help to control previously untreated CLL/SLL.
Who Is on the Research Team?
Nitin Jain, MBBS
Principal Investigator
UT MD Anderson
Are You a Good Fit for This Trial?
This trial is for adults diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not received any prior treatment for their disease.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Obinutuzumab
- Sonrotoclax
- Zanubrutinib
Trial Overview
Researchers are studying a combination of three drugs—zanubrutinib, sonrotoclax, and obinutuzumab—to see if they can help control CLL/SLL in people who haven't been treated before. All participants receive all three drugs.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Each cycle will be 4 weeks in length. Participants will receive zanubrutinib orally 320 mg once daily continuously starting Cycle 1 Day 1 (C1D1) and will continue as monotherapy through cycle 3. Starting in cycle 4, participants will receive sonrotoclax orally starting C4D1 with a weekly dose escalations schedule to a target dose of 320 mg daily in combination with zanubrutinib. Participants will continue combination therapy with zanubrutinib and sonrotoclax from Cycle4 through Cycle 15 (12 cycles total). Obinutuzumab will be added starting in cycle 10 and given for 6 cycles (Cycles 10-15).
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
BeOne Medicines
Industry Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.